Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab

키워드

참고문헌 (35)

1. Lalwani GA, "A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study", Am J Ophthalmol, 148, pp.43~58 (2009)
2. Engelbert M, "“Treat and extend”dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization", retinal angiomatous proliferation, 2009, pp.29, 1424~1431
3. Regillo CD, "Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1", Am J Ophthalmol, 145, pp.239~248 (2008)
4. Rosenfeld PJ, "Ranibizumab: phase III clinical trial results", Ophthalmol Clin North Am, 19, pp.361~372 (2006)
5. Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
6. Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
7. Kawasaki R, "Is bilateral age-related macular degeneration less common in Asians than Caucasians?", Ophthalmic Epidemiol, 18, pp.253~258 (2011)
8. Macular Photocoagulation Study Group, "Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization", Arch Ophthalmol, 111, pp.1189~1199 (1993)
9. Mahajan VB, "Bilateral intravitreal injection of antivascular endothelial growth factor therapy", Retina, 31, pp.31~35 (2011)
10. Davis RP, "Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration", Clin Ophthalmol, 4, pp.703~707 (2010)
11. Lima LH, "Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy", Retina, 29, pp.1213~1217 (2009)
12. Bakri SJ, "Bilateral simultaneous intravitreal injections in the office setting", Am J Ophthalmol, 148, pp.66~69 (2009)
13. Hosseini H, "Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration", Retina, 32, pp.967~971 (2012)
14. Matsuyama K, "Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes", J Ocul Pharmacol Ther, 27, pp.379~383 (2011)
15. Al-Dhibi H, "Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema", J AAPOS, 13, pp.400~402 (2009)
16. Wu Z, "Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report", Ann Acad Med Singapore, 37, pp.591~593 (2008)
17. Avery RL, "Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy", Ophthalmology, 113, pp.1695~ (2006)
18. CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
19. Meyer CH, "Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans", Retina, 31, pp.1877~1884 (2011)
20. Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans", Am J Ophthalmol, 146, pp.508~512 (2008)
21. Sato T, "Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity", Am J Ophthalmol, 153, pp.327~333 (2012)
22. Davidovic SP, "Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy", Eur J Ophthalmol, 22, pp.792~798 (2012)
23. Ma Y, "Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab", Am J Ophthalmol, 153, pp.307~313 (2012)
24. Matsuyama K, "Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab", Br J Ophthalmol, 94, pp.1215~1218 (2010)
25. Gismondi M, "Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure", J Glaucoma, 18, pp.658~661 (2009)
26. Falkenstein IA, "Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)", Retina, 27, pp.1044~1047 (2007)
27. Choi DY, "Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib", Retina, 31, pp.1028~1035 (2011)
28. Adelman RA, "Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections", J Ocul Pharmacol Ther, 26, pp.105~110 (2010)
29. Jalil A, "Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication", Eye, 21, pp.1541~ (2007)
30. Semoun O, "Acute angle-closure glaucoma complicating an intravitreal injection of bevacizumab", J Fr Ophtalmol, 32, pp.58~ (2009)
31. Woo SJ, "Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance", Retina, 32, pp.667~671 (2012)
32. Rasier R, "The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension", Eye, 23, pp.1714~1718 (2009)
33. Chung YR, "Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology", Eye, 24, pp.1320~1324 (2010)
34. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results", Ophthalmology, 119, pp.1388~1398 (2012)
35. IVAN Study Investigators, "Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial", Ophthalmology, 119, pp.1399~1411 (2012)

관련 논문AI추천